Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2018 1
2019 1
2020 3
2021 1
2022 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Renso R, Randi ML, Bertozzi I, Loscocco GG, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, De Stefano V, Patrono C; Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Rocca B, et al. Among authors: renso r. Am J Hematol. 2024 Aug;99(8):1462-1474. doi: 10.1002/ajh.27418. Epub 2024 Jun 15. Am J Hematol. 2024. PMID: 38877813 Free article. Clinical Trial.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F. Maffioli M, et al. Among authors: renso r. Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. Blood Adv. 2019. PMID: 31698448 Free PMC article.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Elli EM, Di Veroli A, Bartoletti D, Iurlo A, Carmosino I, Benevolo G, Abruzzese E, Bonifacio M, Bergamaschi M, Polverelli N, Caramella M, Cilloni D, Tiribelli M, Pugliese N, Caocci G, Crisà E, Porrini R, Markovic U, Renso R, Auteri G, Cattaneo D, Trawinska MM, Scaffidi L, Biale L, Bucelli C, Breccia M, Gambacorti-Passerini C, Palumbo GA, Latagliata R, Palandri F. Elli EM, et al. Among authors: renso r. Br J Haematol. 2022 Apr;197(2):190-200. doi: 10.1111/bjh.18057. Epub 2022 Feb 8. Br J Haematol. 2022. PMID: 35137397 Free article.
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine.
Fontana D, Mauri M, Renso R, Docci M, Crespiatico I, Røst LM, Jang M, Niro A, D'Aliberti D, Massimino L, Bertagna M, Zambrotta G, Bossi M, Citterio S, Crescenzi B, Fanelli F, Cassina V, Corti R, Salerno D, Nardo L, Chinello C, Mantegazza F, Mecucci C, Magni F, Cavaletti G, Bruheim P, Rea D, Larsen S, Gambacorti-Passerini C, Piazza R. Fontana D, et al. Among authors: renso r. Nat Commun. 2020 Nov 23;11(1):5938. doi: 10.1038/s41467-020-19721-w. Nat Commun. 2020. PMID: 33230096 Free PMC article.
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
Bossi E, Aroldi A, Brioschi FA, Steidl C, Baretta S, Renso R, Verga L, Fontana D, Sharma GG, Mologni L, Mussolin L, Piazza R, Gambacorti-Passerini C. Bossi E, et al. Among authors: renso r. Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3. Am J Hematol. 2020. PMID: 32808682 Free article. Clinical Trial. No abstract available.